Cedars-Sinai Biomanufacturing vs CTMC: CDMO Comparison
Side-by-side comparison of Cedars-Sinai Biomanufacturing and CTMC on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Cedars-Sinai Biomanufacturing has FDA inspections on record (1); CTMC does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Cedars-Sinai Biomanufacturing appears as a manufacturing partner on more matched clinical programs (31 vs 0) — a broader sponsor book.
- Composite Signal Score: Cedars-Sinai Biomanufacturing 79/100 vs CTMC 63/100 — a 16-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Cedars-Sinai Biomanufacturing and CTMC qualify as Cell Therapy manufacturers; Cedars-Sinai Biomanufacturing carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Cedars-Sinai Biomanufacturing and CTMC qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Cedars-Sinai Biomanufacturing vs CTMC
Which has the stronger FDA inspection record, Cedars-Sinai Biomanufacturing or CTMC?
Both Cedars-Sinai Biomanufacturing and CTMC maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Cedars-Sinai Biomanufacturing has 1 FDA inspection on record; CTMC has 0.
Which is more active in clinical-stage manufacturing — Cedars-Sinai Biomanufacturing or CTMC?
Cedars-Sinai Biomanufacturing is matched to 31 ClinicalTrials.gov records as a manufacturing partner; CTMC is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Cedars-Sinai Biomanufacturing or CTMC?
Both Cedars-Sinai Biomanufacturing and CTMC are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Cedars-Sinai Biomanufacturing carries a Signal Score of 79/100 and CTMC carries 63/100 — a meaningful lead for Cedars-Sinai Biomanufacturing. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →